Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $105M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 19.05.2025 | Forbion | forbion.co... |
| - | Syncona Pa... | synconaltd... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.10.2024 | Series B | $105M | - |
Mentions in press and media 3
| Date | Title | Description |
| 09.10.2024 | Purespring Therapeutics Raises $105M in Series B Financing | Purespring Therapeutics, a London, UK-based gene therapy company focused on enhancing the treatment of kidney diseases, raised $105M in Series B funding. The round was led by Sofinnova Partners, in collaboration with a syndicate including G... |
| 09.10.2024 | Purespring bottles up $105M series B to bring kidney disease gene therapy to the clinic | London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. The oversubscribed round was led by Sofinnova Partne... |
| - | Purespring Therapeutics | “Home - Purespring Therapeutics” |